There are currently 603 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996
Recruiting
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination wit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Early Breast Cancer
Register for Updates
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934
Recruiting
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/03/2024
Locations: Research Site, Omaha, Nebraska
Conditions: ER-Positive HER2-Negative Breast Cancer
Register for Updates
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141
Recruiting
The purpose of this study is to evaluate the safety and tolerability of: AB521 when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and AB521 monotherapy and AB521 in combination with cabozantinib in participants with ccRCC in the dose expansion stage
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Nebraska Cancer Specialists - Oncology Hematology West PC, Omaha, Nebraska
Conditions: Clear Cell Renal Cell Carcinoma, Solid Tumors
Register for Updates
Amulet™ ADVANCE LAA
NCT05997446
Recruiting
This is a prospective, multicenter, observational study intended to characterize real-world outcomes on the commercially available Amulet device in the United States. The study will enroll approximately 1000 subjects at up to 50 US clinical sites. Subjects will be followed through 24 months in accordance with each site's standard care practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: CHI Health Creighton University Medical Center-Bergan Mercy, Omaha, Nebraska
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
All
Ages:
All
Trial Updated:
06/03/2024
Locations: Not set, Omaha, Nebraska
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
NCT05822583
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: University of Nebraska Medical Center (Site 080-045), Omaha, Nebraska
Conditions: COVID-19
Register for Updates
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
NCT05224102
Recruiting
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Stanley Truhlsen Eye Institute, Omaha, Nebraska
Conditions: Diabetic Macular Edema
Register for Updates
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )
NCT05568888
Recruiting
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.
Gender:
All
Ages:
15 years and above
Trial Updated:
06/03/2024
Locations: UNMC (University of Nebraska Medical Center), Omaha, Nebraska
Conditions: Traumatic Injury
Register for Updates
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887
Recruiting
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Gender:
All
Ages:
Between 50 years and 70 years
Trial Updated:
05/31/2024
Locations: Nebraska Medicine-Village Pointe, Omaha, Nebraska +1 locations
Conditions: Stage I Breast Cancer
Register for Updates
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
NCT05583526
Recruiting
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Gender:
All
Ages:
12 years and above
Trial Updated:
05/31/2024
Locations: Skin Specialists, PC, Omaha, Nebraska
Conditions: Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Register for Updates
Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine
NCT05516992
Recruiting
The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: OrthoNebraska, Omaha, Nebraska
Conditions: Lumbar Degenerative Disc Disease
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
Female
Ages:
Between 18 years and 60 years
Trial Updated:
05/31/2024
Locations: Nebraska Medicine-Village Pointe, Omaha, Nebraska +5 locations
Conditions: Breast Cancer
Register for Updates